ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3128-Box-Hill-Box-Hill-Hospital-Eastern-Health
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
49
trial(s) found.
NCT07623200
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (
EXCALIBUR-ET2
)
anti-CALR monoclonal antibody
Essential thrombocythaemia
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT07527819
Curative
Not yet recruiting
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC) (
FERTILE
)
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2060 - North Sydney - Mater Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT07519772
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma (
WaveSpan-008
)
bispecific T-cell engager,CD19-targeting
Lymphoma
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4812 - Townsville - Townsville University Hospital
NCT07518186
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (
TRIlogy-5
)
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
trispecific T-cell engager,BCMA/GPRC5D-targeting
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
NCT07300943
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of CLIO-8221 in Patients With Advanced Solid Tumors (
CLIO-8221-001
)
anti-ERBB2 antibody-drug conjugate,topoisomerase/ATR inhibitor-payload
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT07287150
Advanced
Phase 2
Recruiting
A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (
InavoPC
)
PI3K alpha inhibitor
antiandrogen,nonsteroidal,second generation
taxane
Castrate-resistant prostate cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
NCT07284849
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (
INCA033890-303
)
anti-VEGF monoclonal antibody
bispecific TGFBR2/PD-1 antibody
Colorectal adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07258511
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody (
TRIlogy-4
)
trispecific T-cell engager,BCMA/GPRC5D-targeting
Multiple myeloma
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT07224672
Haem
Phase 2
Recruiting
A Phase 2, Open-label, Randomized, Dose Optimization Study Evaluating the Efficacy and Safety of Belantamab Mafodotin Administered in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain Amyloidosis (
ALANIS
)
alkylating agent
anti-BCMA-immunoconjugate
glucocorticoid
proteasome inhibitor
AL amyloidosis
NSW
2145 - Westmead - The Children's Hospital at Westmead
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT07218380
Advanced
Phase 3
Recruiting
FORAGER-2
: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration
FGFR3 inhibitor
anti-NECTIN4 antibody-drug conjugate
anti-PD-1 monoclonal antibody
placebo
Urothelial carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07214779
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (
MAESTRA-2
)
CDK2 inhibitor
Ovarian cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT07052903
Haem
Phase 3
Recruiting
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) (
ALN-TTRSC04-003
)
placebo
siRNA therapy,TTR-targeting
Transthyretin Amyloidosis
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6027 - Joondalup - Joondalup Health Campus
NZ
NZ.2025 - Papatoetoe - Aotearoa Clinical Trials - Middlemore Hospital
NZ.3210 - Hamilton - Waikato Hospital
NZ.8011 - Christchurch - New Zealand Clinical Research
NCT07011719
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (
PEAK-1
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
HIF2a inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
placebo
Clear cell renal cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3010 - Rotorua - Rotorua Hospital
NZ.3210 - Hamilton - Waikato Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT07007312
Haem
Phase 3
Recruiting
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia (
KO-MEN-017
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
menin-MLL1 inhibitor
placebo
Acute myeloid leukaemia
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06932562
Haem
Phase 3
Recruiting
A Randomized, Open-Label, Controlled Phase 3 Study of Comparing Daratumumab, Lenalidomide and Dexamethasone Induction Followed by Linvoseltamab Versus Continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients (
EMN39
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06830850
Advanced
Phase 1
Recruiting
A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer (
HRS-5041-103
)
AR PROTAC degrader
Castrate-resistant prostate cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06827236
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer (
BNT323-03
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
bispecific PD-L1/VEGFA antibody
Breast cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5000 - Adelaide - Cancer Research SA
NCT06742996
Haem
Phase 3
Recruiting
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (
BGB-11417-302
)
BTK inhibitor
Bcl2 inhibitor
placebo
Mantle cell lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - One Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT06697301
Advanced
Phase 2 / Phase 3
Recruiting
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006) (
EIK1001-006
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
placebo
Melanoma
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4032 - Chermside - Icon Cancer Care Chermside
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06679101
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (
DREAMM-10
)
anti-BCMA-immunoconjugate
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06594926
Curative
Phase 2
Recruiting
Evaluating the Efficacy of Bipolar Androgen Therapy in Extending Metastasis-free Survival in Patients With M0 Castrate-resistant Prostate Cancer With PSA Progression But Not Radiological or Clinical Progression on Darolutamide (
WOMBAT
)
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3677 - Wangaratta - Northeast Health Wangaratta
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06588478
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
BTK inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Perth Blood Institute
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06561386
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1% (
RELATIVITY1093
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4120 - Greenslopes - Greenslopes Private Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06561048
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (
CPI-818-004
)
ITK inhibitor
Anaplastic large cell lymphoma
Angioimmunoblastic T-cell lymphoma
Lymphoma
Peripheral T-cell lymphoma
T-cell lymphoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2217 - Kogarah - St George Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06499285
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW) (
KER-050-D301
)
modified ActRIIA ligand trap protein
placebo
Myelodysplastic syndrome
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - ICON Cancer Care
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT06435429
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment (
JZP598-303
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-ERBB2 monoclonal antibody
bispecific ERBB2/ERBB2 antibody
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3149 - Mount Waverley - Waverley Private Hospital - Oncology
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06366789
Haem
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) (
ZE46-0134-0002
)
pan-FLT3/IRAK4 inhibitor
Solid tumour
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6009 - Nedlands - Linear Clinical Research
NCT06284317
Curative
Phase 3
Recruiting
An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC (
ADOPT-lung
)
anti-PD-L1 monoclonal antibody
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06244771
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors (
PROSPER
)
KRAS G12C inhibitor,ON/OFF-state inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Tasman Oncology
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NCT06158854
Haem
Phase 1 / Phase 2
Recruiting
An Open-Label Phase 1/2 Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis (
M24-209
)
bispecific T-cell engager,BCMA-targeting
Solid tumour
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06128629
Haem
Phase 3
Recruiting
MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) (
ITL-2001-CL-301
)
CRISPR-Cas9 gene-editing therapy,TTR-targeting
placebo
Solid tumour
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05866458
Curative
Recruiting
Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy (
ROSALIE
)
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2060 - North Sydney - Mater Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2487 - Cudgen - Tweed Valley Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3002 - East Melbourne - Victoria Breast & Oncology Care
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3165 - Bentleigh East - Monash Medical Centre - Moorabbin
3844 - Traralgon - Latrobe Regional Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
Clear cell renal cell carcinoma
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
NA
NA
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.9016 - Dunedin - Dunedin Hospital
NCT05393791
Advanced
Phase 2
Recruiting
ANZadapt
: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05303532
Advanced
Phase 3
Enrolling by invitation
ROSY-D
: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
anti-PD-L1 monoclonal antibody
Cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
NCT04728893
Haem
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (
1026-003
)
BTK inhibitor
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Small lymphocytic lymphoma
Waldenström Macroglobulinaemia
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04419649
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (
KER050-MD-201
)
modified ActRIIA ligand trap protein
Myelodysplastic syndrome
NA
2025 - Papatoetoe - Middlemore Hospital
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT04176198
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis (
BBI-TP-3654-102
)
PIM1 kinase inhibitor,selective
Myelofibrosis
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT02582697
Advanced
Phase 3
Recruiting
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (
P3BEP
)
Bleomycin
Cisplatin
Etoposide
Filgrastim
Pegfilgrastim
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Germ cell tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.1023 - Grafton - Starship Children's Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12625001091493
Curative
Not Applicable
Recruiting
The
FERTILE
Study: Evaluating ovarian toxicity outcomes following immunotherapy in patients with Triple-Negative Breast Cancer (TNBC)
Breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2060 - North Sydney - Mater Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12625000994482
Haem
Phase 1 / Phase 2
Not yet recruiting
ALLG AMLM28/A2 (ADAPT): Achieving Durable remissions via Adaptive Pro-survival Targeting in acute myeloid leukaemia (AML)) – VEN/AZA/Pelcitoclax. A therapeutic arm of the ALLG AMLM28 ADAPT Study-Master Protocol. (
ADAPT-A2
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12625000438459
Haem
Phase 2
Recruiting
A Centralized Platform study for Functional High Risk Multiple Myeloma: Domain 1 - Talquetamab and Teclistamab (
ZEPFHR-MM-Domain-1
)
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12625000429459
Haem
Phase 2
Recruiting
A Centralized Platform study for Functional High Risk Multiple Myeloma - Master Protocol (
ZEPFHR-MM
)
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12624000582550
Curative
Phase 2
Recruiting
Evaluating the efficacy of bipolar androgen therapy in extending metastasis-free survival in patients with M0 castrate-resistant prostate cancer with prostate specific antigen progression but not radiological or clinical progression on darolutamide (
WOMBAT
) - ANZUP 2201
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3677 - Wangaratta - Northeast Health Wangaratta
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12623000900617
Haem
Phase 2
Recruiting
AMLM28 Platform Study (Master Protocol) - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy (
ALLG
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12622000180718
Curative
Not Applicable
Not yet recruiting
Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (
SPACE-FLOT
): An international multicentre cohort study
Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
taxane
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT05182931
Advanced
Phase 2
Unknown
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (
I-FIRST
Study)
BRAF V600 inhibitor
BRAF inhibitor
Dabrafenib
MEK inhibitor
RAF inhibitor
Trametinib
cancer therapy
cancer therapy,BRAF-targeting
cancer therapy,BRAF V600-targeting
cancer therapy,MEK-targeting
cancer therapy,RAF-targeting
NOT Anaplastic thyroid cancer
Thyroid cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3181 - Prahran - The Alfred Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (44)
Not yet recruiting (3)
Enrolling by invitation (1)
Unknown (1)
Recruitment Country and State
VIC (49)
NSW (43)
QLD (39)
WA (31)
SA (28)
ACT (10)
TAS (9)
NZ (9)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (7)
Phase 2 (12)
Phase 2 / Phase 3 (1)
Phase 3 (22)
Trial Type
Haem (24)
Advanced (17)
Curative (8)
Cancer Therapy Class
PD-1/PD-L1
16%
BCMA
10%
AR
10%
androgen axis
10%
PD-1
10%
cereblon
8%
Bcl2
8%
ERBB2
6%
DNA methyltransferase
6%
PD-L1
6%
BTK
6%
oestrogen axis
6%
CYP17A1
4%
proteasome
4%
AXL
4%
HIF2a
4%
KIT
4%
MET
4%
RET
4%
ROS1
4%
VEGFR
4%
VEGFR2
4%
CD38
4%
LHRH
4%
CALR
2%
CD19
2%
ATR
2%
PI3Kalpha
2%
TGFBR2
2%
VEGF
2%
FGFR
2%
FGFR3
2%
Nectin4
2%
CDK2
2%
KMT2A
2%
menin-MLL1
2%
menin
2%
VEGFA
2%
TLR7/TLR8
2%
LAG3
2%
DHFR
2%
HDAC
2%
ITK
2%
ER
2%
FLT3
2%
KRAS
2%
TTR
2%
CTLA4
2%
JAK1
2%
JAK2
2%
GPRC5D
2%
BRAF
2%
BRAF V600
2%
MEK
2%
RAF
2%
Facility
3128 - Box Hill - Box Hill Hospital - Eastern Health (49)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (17)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (15)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (14)
4102 - Woolloongabba - Princess Alexandra Hospital (13)
3000 - Melbourne - Peter MacCallum Cancer Centre (12)
3004 - Melbourne, Southbank - Alfred Health (12)
5042 - Bedford Park - Flinders Medical Centre (11)
2605 - Garran - The Canberra Hospital (10)
3168 - Clayton - Monash Medical Centre (10)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (10)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (10)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (10)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (10)
2050 - Camperdown - Chris O'Brien Lifehouse (9)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (8)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (8)
6150 - Murdoch - Fiona Stanley Hospital (8)
3065 - Fitzroy - St Vincent's Hospital Melbourne (8)
4575 - Birtinya - Sunshine Coast University Hospital (7)
2109 - North Ryde - Macquarie University Hospital (7)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (7)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (7)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (6)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (6)
7000 - Hobart - Royal Hobart Hospital (6)
2170 - Liverpool - Liverpool Hospital (5)
5112 - Elizabeth Vale - Lyell McEwin Hospital (5)
6009 - Nedlands - Linear Clinical Research (5)
3066 - Epping - Northern Hospital (5)
2065 - St Leonards - GenesisCare North Shore Private Hospital (5)
2076 - Wahroonga - Sydney Adventist Hospital (5)
NZ.9016 - Dunedin - Dunedin Hospital (5)
6000 - Perth - Royal Perth Hospital (4)
2060 - North Sydney - Mater Hospital (4)
2031 - Randwick - Prince of Wales Hospital (4)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (4)
2139 - Concord - Concord Repatriation General Hospital (4)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (3)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (3)
7000 - Hobart - ICON Cancer Care Hobart (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (3)
2500 - Wollongong - Wollongong Hospital (3)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
3021 - St Albans - Western Health - Sunshine Hospital (3)
4032 - Chermside - The Prince Charles Hospital (3)
4032 - Chermside - Icon Cancer Care Chermside (3)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (3)
2640 - Albury - Border Medical Oncology Research Unit (3)
2217 - Kogarah - St George Hospital (3)
NA
2031 - Randwick - Scientia Clinical Research Ltd (2)
4215 - Southport - Gold Coast University Hospital (2)
4812 - Hyde Park - Icon Cancer Centre Townsville (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (2)
5000 - Adelaide - Cancer Research SA (2)
6005 - West Perth - Perth Blood Institute (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
2500 - Wollongong - Cancer Care Wollongong (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
3677 - Wangaratta - Northeast Health Wangaratta (2)
2200 - Bankstown - Bankstown-Lidcombe Hospital (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
3121 - Richmond - Epworth Freemasons Hospital (2)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
4812 - Townsville - Townsville University Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
6027 - Joondalup - Joondalup Health Campus (1)
NZ.2025 - Papatoetoe - Aotearoa Clinical Trials - Middlemore Hospital (1)
NZ.8011 - Christchurch - New Zealand Clinical Research (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
NZ.3010 - Rotorua - Rotorua Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
6009 - Nedlands - One Clinical Research (1)
6168 - Cooloongup - Rockingham Hospital (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
3135 - Ringwood East - Maroondah Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4215 - Southport - ICON Cancer Care (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
3149 - Mount Waverley - Waverley Private Hospital - Oncology (1)
4215 - Southport - Tasman Oncology (1)
4870 - Cairns - Cairns Base Hospital (1)
2487 - Cudgen - Tweed Valley Hospital (1)
3002 - East Melbourne - Victoria Breast & Oncology Care (1)
3165 - Bentleigh East - Monash Medical Centre - Moorabbin (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2025 - Papatoetoe - Middlemore Hospital
2485 - Tweed Heads - The Tweed Hospital (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
3011 - Footscray - Footscray Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
3181 - Prahran - The Alfred Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Plasma cell disorder
Urogenital cancer
Multiple myeloma
Breast cancer
Lymphoma
Male genital cancers
Prostate cancer
Leukaemia
Myeloproliferative neoplasm
Non-Hodgkin's lymphoma
Thoracic cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Gastrointestinal cancer
Acute myeloid leukaemia
Myeloid leukaemia
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Breast adenocarcinoma
Colorectal cancer
Lower gastrointestinal cancer
Amyloidosis
Clear cell renal cell carcinoma
Kidney cancer
Mantle cell lymphoma
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
Myelodysplastic syndrome
Upper gastrointestinal cancer
Essential thrombocythaemia
Triple-negative breast cancer
Colorectal adenocarcinoma
AL amyloidosis
Urothelial carcinoma
Gynaecological cancer
Ovarian cancer
Transthyretin Amyloidosis
Melanoma
Anaplastic large cell lymphoma
Angioimmunoblastic T-cell lymphoma
Peripheral T-cell lymphoma
T-cell lymphoma
HER2-positive breast cancer
Pancreatic cancer
Pancreatobiliary cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
High-grade B-cell lymphoma
Marginal zone lymphoma
Waldenström Macroglobulinaemia
Myelofibrosis
Germ cell tumour
Gastric adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Endocrine gland cancer
Thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy